Scientific Advisors for TSO
Joel V. Weinstock, M.D.
Tufts New England Medical Center
Joel V. Weinstock, M.D. is Chief of the Division of Gastroenterology/Hepatology at Tufts New England Medical Center. He received his medical training at the University of Michigan. He was Chief of the Center for Digestive Disease at the University of Iowa prior coming to his appointment at Tufts. Dr. Weinstock is a world authority on inflammatory conditions of the intestine. His clinical specialty is in inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. He has active research programs both in clinical studies related to inflammatory bowel disease as well as in basic mechanisms of immune regulation.
David E. Elliott, M.D., PH.D.
University of Iowa Carver College of Medicine
David E. Elliott, M.D., Ph.D. is the James A. Clifton Chair of Gastroenterology and Director of the Division of Gastroenterology & Hepatology at the University of Iowa Carver College of Medicine. He received his Ph.D. in Immunology & Microbiology at Wayne State University in Detroit, Michigan studying the immune response to the helminths. He received his M.D. from the same institution then performed his residency in Internal Medicine at Johns Hopkins Hospital in Baltimore, Maryland. He moved to Iowa for fellowship training in Gastroenterology & Hepatology studying with Dr. Joel Weinstock. After fellowship, Dr. Elliott joined the faculty of the University of Iowa. In the laboratory, he studies how helminths influence the immune system to suppress inflammation. In the clinic, he cares for patients with immune-mediated inflammatory diseases of the stomach and intestine.
William J. Sandborn, M.D.
UC San Diego Health System
William J. Sandborn, M.D. completed medical school and an internal medicine residency at Loma Linda University in Loma Linda California. He completed a gastroenterology fellowship at the Mayo Clinic in Rochester Minnesota in 1993. From 1993-2010, he was on the faculty of the Mayo Clinic, rising to Professor of Medicine, Vice Chairman of the Division of Gastroenterology and Hepatology, and Associate Dean of Research for Intellectual Property and Industry Relations. In 2011 he became Professor of Clinical Medicine at the University of California San Diego and Director of the IBD Center and Chief of the Division of Gastroenterology for the UC San Diego Health System. Dr. Sandborn has published over 393 peer reviewed articles including articles in the New England Journal of Medicine, the Lancet, JAMA, the Annals of Internal Medicine, and Gastroenterology. His research interests are clinical trials and clinical pharmacology related to inflammatory bowel disease.
Scientific Advisors for CNDO-109
Stephen D. Nimer, M.D.
Sylvester Comprehensive Cancer Center
Stephen D. Nimer, M.D., is Director of the Sylvester Comprehensive Cancer Center at the University of Miami, Florida. Dr. Nimer was at Memorial Sloan-Kettering Cancer Center ("MSKCC") in New York for nearly 20 years, where he held the Alfred P. Sloan Chair and served as Head of the Division of Hematologic Oncology, Vice Chairman for Faculty Development, and Chief of the Hematology Service. Dr. Nimer is an expert in the treatment of adult hematologic malignancies (or cancers of the blood) including leukemia and myelodysplastic syndromes ("MDS"). At MSKCC, he established the inpatient hematology service and the autologous stem cell transplantation program for hematologic malignancies. Dr. Nimer has published extensively on the topics of leukemia and MDS with over 200 citations in the PubMed index covering a range of disciplines from basic science to applied clinical research. While at MSKCC, Dr. Nimer ran a very active laboratory that received one of two awards given to U.S. investigators by The Leukemia & Lymphoma Society as a Specialized Center of Research in myeloid malignancies. Board-certified in internal medicine, medical oncology and hematology, Dr. Nimer received his medical degree from the University of Chicago School of Medicine, and completed his residency and fellowship at University of California, Los Angeles, School of Medicine.
Mark William Lowdell, BSc, MSc, Ph.D., FRCPath, MICR
Royal Free Hospital, UCL Medical School, and University College of London.
Mark William Lowdell, BSc, MSc, Ph.D., FRCPath, MICR. is Director of Cellular Therapy and BioBanking at the Royal Free Hospital and UCL Medical School and is Senior Lecturer in Hematology at University College of London ("UCL"). He is an internationally renowned expert on clinical immunology and cellular therapy for cancer and a member of multiple international professional and scientific bodies and UK government advisory boards, and commercial advisory boards. He is the recipient in millions of dollars in grant awards and fellowships and is the author of several hundred scientific publications and patents. Dr. Lowdell built and manages the only laboratory in the UK accredited for the production of human cell therapies to full cGMP compliance, the facility which produced activated NK cells for Coronado's initial Phase 1 clinical trial in acute myeloid leukemia. Coronado's core technology for activating NK cells for the treatment of AML and other cancers such as multiple myeloma, prostate, breast, and colon, is derived from licensed patents and know-how from Dr. Lowdell's program at UCL.
Jeffrey Miller, M.D.
Masonic Cancer Center at the University of Minnesota
Jeffrey Miller, M.D. serves as Associate Director, Experimental Therapeutics at the Masonic Cancer Center at the University of Minnesota. Dr. Miller's research interests include natural killer cell therapy to treat cancer. Board-certified in internal medicine, medical oncology and hematology, Dr. Miller received his medical degree from Northwestern University School of Medicine, and completed his residency at the University of Iowa and fellowship at the University of Minnesota.